RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
GC Biopharma Stock

GC Biopharma Liabilities 2024

GC Biopharma Liabilities

1.34 T KRW

Ticker

006280.KS

ISIN

KR7006280002

In 2024, GC Biopharma's total liabilities amounted to 1.34 T KRW, a 12.16% difference from the 1.2 T KRW total liabilities in the previous year.

GC Biopharma Aktienanalyse

What does GC Biopharma do?

GC Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing GC Biopharma's Liabilities

GC Biopharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating GC Biopharma's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing GC Biopharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

GC Biopharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in GC Biopharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about GC Biopharma stock

What is the level of liabilities of GC Biopharma this year?

GC Biopharma has a debt balance of 1.34 T KRW this year.

What were the liabilities of GC Biopharma compared to the previous year?

The liabilities of GC Biopharma have increased by 12.16% increased compared to the previous year.

What are the consequences of high debt for investors of GC Biopharma?

High liabilities can pose a risk for investors of GC Biopharma, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in GC Biopharma?

Low liabilities mean that GC Biopharma has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of GC Biopharma affect the company?

An increase in liabilities of GC Biopharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of GC Biopharma affect the company?

A decrease in the liabilities of GC Biopharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of GC Biopharma?

Some factors that can influence the liabilities of GC Biopharma include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of GC Biopharma so important for investors?

The liabilities of GC Biopharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can GC Biopharma take to modify the liabilities?

To change its liabilities, GC Biopharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does GC Biopharma pay?

Over the past 12 months, GC Biopharma paid a dividend of 1,500 KRW . This corresponds to a dividend yield of about 0.99 %. For the coming 12 months, GC Biopharma is expected to pay a dividend of 1,554.78 KRW.

What is the dividend yield of GC Biopharma?

The current dividend yield of GC Biopharma is 0.99 %.

When does GC Biopharma pay dividends?

GC Biopharma pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of GC Biopharma?

GC Biopharma paid dividends every year for the past 22 years.

What is the dividend of GC Biopharma?

For the upcoming 12 months, dividends amounting to 1,554.78 KRW are expected. This corresponds to a dividend yield of 1.03 %.

In which sector is GC Biopharma located?

GC Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von GC Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GC Biopharma from 5/1/2024 amounting to 1,500 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did GC Biopharma pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of GC Biopharma in the year 2023?

In the year 2023, GC Biopharma distributed 1,750 KRW as dividends.

In which currency does GC Biopharma pay out the dividend?

The dividends of GC Biopharma are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von GC Biopharma

Our stock analysis for GC Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GC Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.